Compare Roblox Corp (RBLX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Roblox Corp trades at $44.68 (market cap $32.02B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.2× Roblox Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| RBLX | VRTX | |
|---|---|---|
Market Cap | $32.02B | $134.06B |
Sector | Media | Health |
52-Week High | $141.56 | $557.96 |
52-Week Low | $35.54 | $376.62 |
Enterprise Value | $30.84B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RBLX trades at $44.82, up 3.49% today, near the consensus price target of $45.71. The stock shows bullish technical signals with strong support at $43 and resistance at $46. Revenue growth is robust, rising to $4.89B in 2025, but net losses persist at -$1.07B. Recent news highlights regulatory scrutiny in the EU and Australia over child safety, alongside positive economic impact from creator earnings.
Outlook remains mixed: strong revenue growth and cash flow improvement support long-term potential, but profitability challenges and regulatory risks weigh on sentiment. Analysts are divided, with 44.7% recommending buy. The key catalyst is achieving sustained profitability amid expanding user engagement.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
